Could a gentler chemo cocktail beat breast cancer with fewer side effects?

NCT ID NCT07421141

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing a less intense chemotherapy regimen for people with early-stage HER2-positive breast cancer. The experimental treatment combines paclitaxel with two targeted drugs (trastuzumab and pertuzumab), skipping the harsher anthracycline drugs. Researchers want to see if this gentler approach can still eliminate all signs of cancer before surgery, while causing fewer side effects. The study includes 186 participants and compares results to a historical group that received standard chemo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Paclitaxel, trastuzumab, and pertuzumab (THP)
What this could lead to
If successful, this could offer a less toxic chemotherapy option for early HER2-positive breast cancer, reducing side effects while maintaining high cure rates.
What could go wrong
This is a phase II study with only 186 participants, so results are preliminary. The experimental regimen may prove less effective than standard treatment, and long-term outcomes are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • P.A. Hertsen Moscow Oncology Research Institute

    Moscow, 125284, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.